Analysis
Implications of “not me” drugs for health systems: lessons from age related macular degeneration
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2941 (Published 01 May 2012) Cite this as: BMJ 2012;344:e2941Data supplement
Web Extra
Extra references w1-w35 supplied by the author
Files in this Data Supplement:
Web Extra
Extra references w1-w35 supplied by the author
Files in this Data Supplement:
Web Extra
Extra references w1-w35 supplied by the author
Files in this Data Supplement:
Related articles
- Feature Published: 01 May 2012; BMJ 344 doi:10.1136/bmj.e3012
- Editorial Published: 01 May 2012; BMJ 344 doi:10.1136/bmj.e2970
- Research Published: 10 June 2010; BMJ 340 doi:10.1136/bmj.c2459
- News Published: 24 April 2012; BMJ 344 doi:10.1136/bmj.e2959
- Letter Published: 22 May 2012; BMJ 344 doi:10.1136/bmj.e3553
- Research Published: 04 July 2012; BMJ 345 doi:10.1136/bmj.e4203
See more
- The BMJ Christmas appeal 2016-7: Orbis, the sight saversBMJ December 01, 2016, 355 i6425; DOI: https://doi.org/10.1136/bmj.i6425
- Leaps in the darkBMJ December 01, 2016, 355 i6447; DOI: https://doi.org/10.1136/bmj.i6447
- NHS spent 8% more on medicines last yearBMJ November 23, 2016, 355 i6320; DOI: https://doi.org/10.1136/bmj.i6320
- Seven days in medicine: 9 to 15 November 2016BMJ November 17, 2016, 355 i6106; DOI: https://doi.org/10.1136/bmj.i6106
- Babies with microcephaly in Brazil are struggling to access careBMJ November 16, 2016, 355 i6157; DOI: https://doi.org/10.1136/bmj.i6157